John Martin - 2010 CEO Pay

John C. Martin

John Martin - Gilead Sciences

Total Compensation: $14.2 million

Details: John Martin's compensation was down a little in 2010 from 2009, when his package was worth just under $14.7 million; last year, it was $14.2 million. Martin earned a salary of a little more than $1.3 million last year--up from $1.24 million in 2009. He also received stock and option awards of roughly $10.5 million--down from the previous year, when he snagged more than $11.1 million.

As Dow Jones notes, Gilead is known for its HIV drugs and saw its net income rise 10 percent to $2.9 billion on revenue growth of 13 percent to $7.9 billion.

Gilead Sciences News:
Truvada fails trial to prevent HIV in women
Who's the biggest HIV drug seller of all?

John Martin - 2010 CEO Pay
Read more on

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.